Introduction
Salivary gland neoplasms are commonly encountered by head and neck surgeons and when malignant account for 8% of all head and neck cancers [1] . Most lesions occur in the parotid gland however cancer specifically of the sublingual gland (SLG) is quite rare and reported only in case reports and small series [2] . More specifically, SLG malignancy often occurs in the fifth decade of life and following appropriate treatment is typically well survived [3] . The overall 5-year survival has been reported at 68% with even improved rates seen in younger patients [3, 4] . Adenoid cystic carcinoma is the most common diagnosis yet many different pathologic etiologies have been reported [5] .
In 1996, Ellis and Auclair classified an aggressive subtype of salivary gland cancer, undifferentiated carcinoma, Abstract NUT midline carcinoma (NMC) is a rare and aggressive disease encountered in the midline of the head and neck or mediastinum. Due to its sparse incidence and subtle pathologic features, we aim to increase knowledge and awareness for this pathologic entity. We present an exemplary case of a young, healthy male presenting with oral cavity pain and cervical lymphadenopathy. This patient was initially diagnosed with an unspecified, highly aggressive sublingual gland malignancy and underwent locoregional resection with free flap reconstruction however suffered a rapid local recurrence and widely extensive metastasis within just 1 month. After rigorous analysis, final pathologic diagnosis revealed a poorly differentiated carcinoma with evidence of squamous differentiation that eventually, post-mortem tested positive for NMC. Only one into three subtypes: lymphoepithelial carcinoma (LEC), small cell (undifferentiated) carcinoma (SCUC), and large cell undifferentiated carcinoma or simply large cell carcinoma (LCUC) [6] . This classification has been largely accepted in the literature and undifferentiated carcinoma remains a rare entity with sparse incidence in the SLG. Alternatively, NUT midline carcinoma (NMC) is another poorly differentiated or undifferentiated squamous carcinoma more recently recognized. It is an exceedingly rare disease with an unknown prevalence due to previous lack of available testing methods and poor clinical awareness. NMC can be a devastating disease and differentiation between these undifferentiated pathologies is critical as treatment plans are quite different.
We present an exemplary case of a NUT midline carcinoma of the sublingual gland in a young, otherwise healthy patient with an unforeseen clinical course. This patient's presentation, diagnosis and rapidly progressive nature of disease are uncharacteristic for salivary gland neoplasms but are typically the case in NMC.
Discussion

Clinical Case
A 26-year old male with no significant past medical history presented to the emergency department with 2 weeks of worsening right-sided oral cavity and submandibular neck pain, swelling, otalgia, and decreased oral intake unresponsive to oral antibiotics. The otolaryngology team was consulted and patient was found to have a full, indurated right floor of mouth with ipsilateral level I through III lymphadenopathy. A CT neck with contrast was obtained showing a 3.0 × 2.3 cm right oral cavity mass as well as multiple right submandibular and lateral chain necrotic lymph nodes (Fig. 1) . The patient was taken to the operating room that night for incision and drainage due to concern for airway compromise. During surgery, a submucosal, granular tumor was encountered and biopsies were sent. Subsequent pathology revealed an undifferentiated carcinoma of the SLG.
Positron emission tomography (PET/CT) was obtained staging the disease as T2 N2b M0 (Fig. 2) . The patient soon underwent resection of right floor of mouth, tongue, mandibular periosteum and supra-omohyoid contents with bilateral neck dissections. The oral cavity was reconstructed with a radial forearm fasciocutaneous free flap. Final pathologic staging of the disease was T4 N2c with 47 of 67 lymph nodes positive for carcinoma. The final pathology was reviewed by our head and neck pathologists and sent for outside consultation due to lack of typical staining patterns and appearance. The only diagnosis determined pathologically could be high-grade undifferentiated or poorly differentiated carcinoma with squamous differentiation of the SLG (Fig. 3) . However, the specimen was later submitted for molecular genetics post-mortem and the carcinoma was found to be positive for rearrangement of the NUTM1 (15q14) locus with fusion of the NUTM1 (15q14) and BRD4 (19p13.12) loci, diagnostic for NMC.
The patient was referred for adjuvant chemoradiation however within just 2 weeks of surgery developed aggressive recurrent and metastatic disease. A PET/CT only 1 month after original imaging showed development of extensive lung and skeletal metastasis (Fig. 2) . Dural metastatic disease was confirmed by MRI. The patient underwent palliative chemo-radiation with docetaxol and cisplatin (both 75 mg/m 2 ) as well as palliative pain control but unfortunately passed away within just 4 months of initial presentation.
Assessment and Diagnosis
Neoplasms of the sublingual gland are rare and but most often malignant in 75% of cases. When any floor-of-mouth mass is identified a thorough history along with head and neck examination including dental exam are important to create a differential diagnosis. This is especially true in young patients where infectious, congenital, and benign masses are more common than malignancy.
In the setting of pain, as was the chief complaint in this case, an infectious etiology must certainly be considered; however a proper history can usually differentiate between patients with infection vs neoplasm. Regardless of the etiology, the primary management of a sublingual gland mass is almost exclusively surgical with pre-operative imaging and incisional or fine needle biopsy as indicated to clarify a diagnosis. This case highlights the importance of sending any tissue for pathology during surgical intervention to confirm a diagnosis. The extent of resection is then determined by the pathology, anatomy, and location of the lesion. If malignancy is diagnosed, prompt management is important as a rich lymphatic network in this region creates an ideal environment for potential tumor spread. As in most cases, tumor size, grade, and histopathology are the key predictors of distant metastasis [7] . Overall survival is typically high with appropriate management.
This case, however, characterizes an unusually aggressive tumor of the SLG. The patient's clinical course was so vivid that the authors elected ongoing work-up after the patient's demise. Eventually the tumor was diagnosed as NMC after identifying the pathognomonic gene rearrangement on FISH analysis.
NUT Midline Carcinoma
NMC is known to represent an aggressive malignancy defined as a poorly or undifferentiated carcinoma in a midline location. Most cases present in the thorax or mediastinum however one-third of cases occur in the head and neck [8] . These lesions arises from a single gene translocation creating the BRD-NUT fusion protein acting to block cellular differentiation and promote uncontrolled growth of tumor cells [9] . This particular balanced chromosomal translocation t(15;19) results in the BRD4-NUT oncogene which bypasses the typical route of accumulated mutations on the way to squamous cell carcinoma. Diagnostic confirmation is typically made by confirming the presence of the NUT proto-oncogene translocation using FISH analysis [10] . Furthermore, immunohistochemical testing is now available using a monoclonal antibody to identify the BRD-NUT fusion protein with reported sensitivity and specificity of 87% and 100% respectively [11] . Unfortunately, despite treatment attempts, this disease has been shown to have rapid progression, hematogenous metastasis, and overall poor survival at a median of 6.7 months [12] .
Recently, a single case of NMC was described in the SLG and it has been previously reported in other salivary tissue as well [10, 13, 14] . Due to its poorly differentiated nature and low clinical awareness however, this diagnosis is likely often missed. First, it requires clinical suspicion based on history, physical exam and pre-operative workup. Then histopathologically, although no pathognomonic features exist, the tumor is identified by round to slightly ovoid, monotonous undifferentiated cells with focal squamous differentiation in 35-40% of its cases [12, 15, 16] . Lastly however, diagnostic confirmation requires proper immunohistochemical staining for the NUT protein typically performed by an outside facility.
In confirming the rare incidence of NMC of the SLG, a complete review of the literature was performed (Table 1) including forty-eight previous case reports or series regarding SLG cancer. Overall, there were 17 different diagnoses reported with a 1.3 male to female ratio. The mean age at diagnosis was 54 years and only 4.6% of cases were reported in patients 30 years of age or younger. In addition, a report of previously reviewed data from the SEER database from 1973 to 2004 found only three cases of SLG cancer in patients under the age of 30 years [4] . Reported treatment modalities, when described, are largely surgical with or without adjuvant therapy. Only three cases were treated primarily without surgery when lymphoma was excluded and two of these patients were over the age of 60 years.
Many different SLG histopathologic diagnoses are reported ( Table 1) . As expected, adenoid cystic carcinoma was most encountered in the literature (45%). Mucoepidermoid carcinoma was second most common (19%). Other diagnoses included adenocarcinoma, acinic cell, salivary duct, basal cell, clear cell and myoepithelial carcinoma, malignant pleomorphic adenoma, transformed carcinoma ex pleomorphic, as well as other less common lesions. Only one report of NMC exists to our knowledge [10] .
Due to its midline location and difficult to interpret pathologic features, NMC can be misdiagnosed as salivary gland undifferentiated carcinoma although this too is uncommon in the SLG. Undifferentiated carcinoma has been reported in other major salivary glands but was not found in our review of the literature in the SLG [6] . By definition, these tumors lack the histomorphologic features of squamous or glandular carcinoma as well as any other specific types of salivary gland neoplasia.
Undifferentiated Carcinoma
In order to more precisely define undifferentiated carcinoma, three subtypes have been described (Table 2) : SCUC, LEC, LCUC. SCUC is neuroendocrine in nature and characterized by smaller cells with typical molding patterns on routine staining. It is an aggressive neoplasm and metastasis is always a consideration.
Lymphoepithelial carcinoma and LCUC both consist of large cells, but can usually be distinguished from one another pathologically and by clinical course. LEC is a tumor characterized by large epithelial cells within a dense lymphoid stroma [83] . EBV positivity is usually associated with this disease in endemic areas (i.e. southern China, Greenland, Alaska) but can occasionally be found in nonendemic areas [84, 85] . In the oropharynx, HPV has been found to associate with LEC as well [86] . Overall 5-year survival is quite good and reported as high as 86% for all ages [83] . Alternatively, LCUC and SCUC lacks any type of differentiation, although some cases have been described to show neuroendocrine features by immunohistochemistry or electron microscopy. It is a rare carcinoma which usually occurs in patients over the age of 60 years. Most involve the parotid gland, but minor salivary gland origin has also been reported [87] .
Similarly, SCUC and LCUC have an aggressive behavior with poor overall prognosis. Locoregional disease is found in a majority of patients with up to 75% of cases diagnosed at stage 4. The overall 5-year survival is under 40% despite initiation of aggressive management [83] . To our knowledge, no cases of SCUC or LCUC have been previously described in the SLG but have been in larger salivary glands. Although the features of these diseases can be similar, with proper work-up and testing, a distinction can be made between these and NMC.
NMC Treatment Considerations
The one previous case of NMC described in the SLG and was found to have a similar biologic behavior to this case. This has also been true for other locations as well with an aggressive metastatic course and early demise despite lack of clear patient risk factors and aggressive treatment. Use of chemotherapy and radiation therapy have been reported with variable responses however outcomes remain poor [12] . Surgery remains a critical part of the treatment algorithm as aggressive upfront resection with negative margins is a significant predictor of overall survival despite adjuvant therapy [16] . Due to the nature of this disease however, [24] ACC ( [39] cure is rare despite an appropriate oncologic resection. Therefore, testing for NMC in patients with similar clinical presentation of a midline, undifferentiated lesion may alter the treatment course. It is essential to test for NMC in this setting in order to provide appropriate pre-operative counseling and consider alternative options including referral for clinical trial enrollment.
As discussed, the oncologic mechanism behind NMC is the function of the BRD4-NUT protein allowing ongoing proliferation and preventing cellular differentiation. This is confirmed by siRNA knock out of the BRD4-NUT oncoprotein however further details of the downstream biologic mechanisms at play remain largely unknown [8] . BRD4 is a known member of the dual bromodomain protein family (BET) that functionally binds acetylated chromatin at these bromodomains [88] . As such, acetylhistone mimics (BETi) can interfere with this domain interaction and has the ability to inhibit the function of the BRD4-NUT protein allowing cellular differentiation to proceed [89] . Novel BETi targeted therapeutics are AcCA acinic cell carcinoma, ACC adenoid cystic carcinoma, AD adenocarcinoma, AD NOS adenocarcinoma not otherwise specified, BCC basal cell carcinoma, CexPA carcinoma ex pleomorphic adenoma, CS carcinosarcoma, EMC Epithelial-myoepithelial carcinoma, HCCC hyaline clear cell carcinoma, LAC lymphadenomatous carcinoma, LEC lymphoepithelial carcinoma, MEC mucoepidermoid carcinoma, PA pleomorphic adenoma, PLGA polymorphous low grade adenocarcinoma, SDC salivary duct carcinoma, SFT solitary fibrous tumor, CT chemotherapy, RT radiation therapy now being investigated in early clinical trials currently enrolling patients. Furthermore, the BRD4-NUT protein is known to bind and activate histone acetyl-transferase p300, hypothesized to acetylate chromatin and create a feed-forward mechanism leading to neoplasia [90] . Histone deacetylase inhibitors artificially increase acetylation leading to BRD4-NUT function reversal and thus a return to regular cellular progression. The use of histone deacetylase inhibitors have shown clinical response in both in-vitro and animal models and more recently, pediatric patients have been treated with histone deacetylase-containing regimens with promising early clinical results [91] .
Conclusion
When managing any floor-of-mouth lesion, one should always keep a high level of suspicion for malignancy regardless of patient's age, demographics, or risk factors. In the setting of a midline lesion with poor or undifferentiated features, especially with focal squamous differentiation, NMC must be considered and we recommend sending genetic testing or immunohistochemical staining for the NUT proto-oncogene. Further knowledge of this disease will improve diagnosis, more accurately define incidence, allow physicians to properly counsel on treatment options, and help identify patients for clinical trial enrollment for much needed prospective evaluation of treatment modalities.
Funding There was no external funding for this project.
Compliance with Ethical Standards
Conflict of interest Nolan Seim declares that he has no conflict of interest. Ramez Phillips declares he has no conflict of interest. Lynn Schoenfield declares that she has no conflict of interest. Theodoros Teknos declares that he has no conflict of interest. James Rocco declares that he has no conflict of interest. Amit Agrawal declares that he has no conflict of interest. Enver Ozer declares that he has no conflict of interest. Ricardo Carrau declares that he has no conflict of interest. Stephen Kang declares that he has no conflict of interest. Matthew Old declares that he has no conflict of interest.
Ethical Approval This article does not contain any studies with human participants or animals performed by any of the authors.
Informed Consent Not indicated for this study.
